Boryung files drug application for novel antihypertensive agent

Published: 2010-03-05 07:00:00

Updated: 2010-03-05 07:00:00

Boryung Pharmaceutical Co., one of Korea's largest pharmaceutical companies, said on March 3 that it has filed an application of a new antihypertensive drug (fimasartan) to the Korea Food and Drug Administration.

Fimasartan is a novel, non-peptide angiotensin II receptor antagonist with a sele...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK